CGTX Key Statistics, Chart & Performance
The current stock price of CGTX is 1.46 USD. In the past year, price increased by 73.81%.
CGTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About CGTX
Company Profile
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Purchase, New York and currently employs 25 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. The company is developing other product candidates in the area of synucleinopathies.
Company Info
COGNITION THERAPEUTICS INC
2500 Westchester Ave
Purchase NEW YORK US
Employees: 25
Phone: 14124812210
COGNITION THERAPEUTICS INC / CGTX FAQ
What does CGTX do?
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company is headquartered in Purchase, New York and currently employs 25 full-time employees. The company went IPO on 2021-10-08. The firm is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. The company is developing other product candidates in the area of synucleinopathies.
What is the stock price of COGNITION THERAPEUTICS INC today?
The current stock price of CGTX is 1.46 USD. The price increased by 4.29% in the last trading session.
What is the dividend status of COGNITION THERAPEUTICS INC?
CGTX does not pay a dividend.
How is the ChartMill rating for COGNITION THERAPEUTICS INC?
CGTX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for CGTX stock?
COGNITION THERAPEUTICS INC (CGTX) currently has 25 employees.
CGTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CGTX. When comparing the yearly performance of all stocks, CGTX is one of the better performing stocks in the market, outperforming 91.94% of all stocks.
CGTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CGTX. While CGTX has a great health rating, there are worries on its profitability.
CGTX Financial Highlights
Over the last trailing twelve months CGTX reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 50.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.49% | ||
| ROE | -76.61% | ||
| Debt/Equity | 0 |
CGTX Forecast & Estimates
10 analysts have analysed CGTX and the average price target is 3.57 USD. This implies a price increase of 144.52% is expected in the next year compared to the current price of 1.46.